MUC1 950-958 (HLA-A*02:01)

The peptide VPGWGIALL is a defined epitope derived from the human Mucin-1 (MUC1) protein and presented by the MHC class I allele HLA-B*07:02. This synthetic peptide is designed for the stimulation and analysis of MUC1-specific CD8⁺ T-cell responses in immunological assays. MUC1 is a transmembrane mucin that is normally expressed on epithelial cells, where it contributes to the protective mucosal barrier. In many malignancies—including breast, ovarian, pancreatic, and bladder cancer—MUC1 is strongly overexpressed and aberrantly glycosylated, which can expose peptide epitopes to the immune system and make the protein an important tumor-associated antigen. As a result, MUC1-derived peptides are widely used in cancer immunology research and in studies investigating antigen-specific T-cell responses. The MUC1 VPGWGIALL peptide (HLA-B*07:02) is synthesized to match the naturally presented epitope and can be used to stimulate antigen-specific T cells in a variety of experimental settings. Typical applications include ELISpot assays, intracellular cytokine staining (ICS), cytotoxicity assays, and T-cell proliferation assays, enabling researchers to monitor and characterize MUC1-directed immune responses. This peptide provides a reliable tool for cancer immunology, antigen-specific T-cell analysis, and immune monitoring studies involving MUC1-associated tumor antigens.

The HUMAN MUC1 Peptide Pool by peptides&elephants is a highly reliable, quality-controlled, overlapping peptide pool covering the complete human Mucin‑1 protein (UniProt ID P15941). The peptide pool is optimized for robust detection and characterization of T-cell responses in immunological research and cancer biomarker discovery. One unit allows the stimulation of 2,5 x 108 cells. The initial set of 311 overlapping 15-mer peptides (with an 11-residue overlap) was reduced to 115 unique peptides by eliminating 196 redundant sequences. Full protein coverage – ensures that all potential epitopes in MUC1 are included Why MUC1 Matters in T‑cell Studies Tumor-associated antigen: MUC1 is a well-known tumor-associated transmembrane mucin heavily overexpressed in many cancers—including breast, bladder, pancreatic and ovarian cancers.  While the regularly glycosylated MUC1 forms a protective barrier on the surface of epithelial cells in healthy tissues, MUC1 is  aberrantly highly expressed,  aberrantly glycosylated and  has altered localization  in cancer cells. It plays significant roles in cell signaling, tumor progression, and immune evasion. T-cell immunogenicity: Numerous MUC1-derived peptides have been validated as CD8⁺ T-cell epitopes in both preclinical models and human studies.  Vaccine and immune monitoring relevance: MUC1 peptide vaccines have been used to induce cytotoxic T‑cell responses in preclinical and clinical settings. Notably, MUC1—also known as Cancer Antigen 15-3 (CA 15-3)—serves as a widely used tumor marker for monitoring disease progression in breast cancer patients. Intended Use of HUMAN MUC1 Peptide Pool  Designed for T‑cell assays, including ELISpot, intracellular cytokine staining (ICS), cytotoxicity assays, proliferation assays, dendritic‑cell pulsing, immune monitoring, T‑cell expansion, and epitope discovery. Also well-suited for cancer biomarker research, especially breast and epithelial cancers.